Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo
NCT07152626Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Mar 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ritlecitinib tosilate in Vitiligo (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoints: Facial Vitiligo Area Scoring Index at 52 weeks and Total Body Vitiligo Scoring Index 50 at 52 weeks. Started Mar 2026; status: recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07152626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152626.